





**Scheme 1.** Reagents and conditions: (a) (i) TMSCl, pyridine; (ii) BzCl; (iii) aq  $\text{NH}_4\text{OH}$ ; (b) 2,2-dimethoxypropane,  $\text{TsOH}\cdot\text{H}_2\text{O}$ , acetone; (c) Mitsunobu reaction, tetrachlorophthalimide,  $\text{PPh}_3$ , THF, 15 h reflux; (d) 75% aq TFA; (e) TBDMSCl,  $\text{AgNO}_3$ , pyridine, DMF; (f) ethylenediamine, THF; (g) MMTrCl,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ; (h) succinic anhydride,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ .

ribonucleic monomers should stabilize oligonucleotide backbones against nucleophilic attack from the 2'-hydroxyl.<sup>7</sup>

Triplex-forming antigene agents with increased affinity for duplex DNA, enable the regulation of gene expression at the transcriptional level and require a miniscule concentration of oligonucleotides in comparison to that which would be required to inhibit the expression of multiple mRNA molecules. While previous experiments have demonstrated the selectivity of DNG, the interaction between template DNA and RNG oligonucleotides has not yet been observed, as RNG monomers for solid-phase synthesis exists only for adenylyl RNG and uridylyl RNG.<sup>7</sup> Our experiment provides a convenient, high-yield, synthesis of the 3'-terminal monomer *N*<sup>4</sup>-benzoyl-2'-*O*-(*tert*-butyldimethylsilyl)-5'-*N*-(4-monomethoxytritylamino)-3'-*O*-succinyl-5'-deoxycytidine **7** (Scheme 1), which may be incorporated into the solid-phase synthesis of cytidyl RNG oligonucleotides. In addition, this monomer can be also used for the solid-phase synthesis of  $\text{P}3' \rightarrow \text{N}5'$  phosphoramidate ribooligonucleotides (5'-amino-RNA, Fig. 1B) with 5'-*O*-nucleotides replaced by 5'-*N*-nucleotides.<sup>11</sup>

For large scale preparations, it was more convenient to perform some reactions directly on the crude from the previous reaction, which did not affect the overall yield. High-yields and pure compounds were obtained and confirmed by gravimetric analysis, TLC, HRMS, and <sup>1</sup>H NMR spectroscopy. Protection of the 2'- and 3'-hydroxyl groups of the pentose ring was performed before running the Mitsunobu reaction on the 5'-hydroxyl group. To a stirred suspension of *N*<sup>4</sup>-benzoylcytidine (30.0 mmol) in acetone (250 mL), *p*-toluenesulfonic acid monohydrate (3.0 mmol) and an excess of 2,2-dimethoxypropane (60 mL) were added. After 24 h reflux, the mixture was filtered to remove the unreacted starting material. The filtrate was concentrated under vacuum and the residue was dissolved with EtOAc, washed with 5%  $\text{NaHCO}_3$  and brine. The

solvent was removed under reduced pressure, and ether was added to induce further precipitation of compound **1** in a 93% yield. Compound **2** was produced by Mitsunobu reaction according to the previously published method.<sup>12,13</sup> To a suspension of **1** (22.2 mmol),  $\text{PPh}_3$  (27.75 mmol) and tetrachlorophthalimide (26.64 mmol) in anhydrous THF (250 mL), diisopropyl azodicarboxylate (26.64 mmol) was added dropwise over 15 min and the mixture was refluxed for 15 h. The solvent was removed under reduced pressure and the crude mixture was purified by silica gel column chromatography (50% EtOAc in hexanes) to afford **2** in an 80% yield. The 2'-, 3'-hydroxyl groups were then deprotected by stirring compound **2** (17.0 mmol) in aqueous trifluoroacetic acid (75%, 100 mL) at RT for 2 h. Compound **3** was obtained in an 89% yield. The low solubility of **3** in organic solvents allowed the precipitation and isolation of the pure compound from the reaction mixture. More convenient was direct conversion of the crude of **2** to a pure precipitate of compound **3**. Protection of the 2'-hydroxyl group with TBDMS was performed to allow for further reactions on the 3'-hydroxyl group. To a solution of **3** (9.3 mmol) in dry DMF (80 mL), pyridine (37.1 mmol) and  $\text{AgNO}_3$  (11.77 mmol) were added. After stirring for 10 min, *tert*-butyldimethylsilyl chloride (11.61 mmol) was added and the reaction mixture was stirred at RT for 24 h. The mixture was filtered through Celite, washed with ethanol, and the filtrate was concentrated in a vacuum. The crude product was purified by silica gel column chromatography (40% EtOAc in hexanes) to give compound **4**.<sup>14</sup> This reaction failed when THF was used as a solvent, likely due to the low solubility of **3** in THF. The 5'-amino nucleoside **5** was generated upon treatment of **4** (2.0 mmol) with ethylenediamine (2.4 mmol) in anhydrous THF (25 mL). The crude of **5** was directly converted to pure compound **6** in an overall yield of 82%. Compound **6** was purified by silica gel column chromatography pre-washed with 2%  $\text{Et}_3\text{N}$  (33% ethyl

acetate in hexanes). Esterification of the 3'-OH with succinic anhydride afforded the loading monomer **7**. Succinic anhydride (3.0 mmol) was added to a mixture of **6** (0.6 mmol) and Et<sub>3</sub>N (6.0 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and the mixture was stirred for 20 h. The solvent was removed under reduced pressure and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>, washed with 5% citric acid, then H<sub>2</sub>O and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in a vacuum. The crude mixture was purified by silica column chromatography pre-washed with 2% Et<sub>3</sub>N (45% EtOAc in hexanes) to afford compound **7** in a 76% yield.<sup>15</sup>

A common initial step in the solid-phase synthesis of oligonucleotides is to covalently attach the 3' moiety of a modified pentose sugar on the first nucleoside to controlled pore glass (CPG), which contains long chain alkylamines.<sup>16</sup> The modifications we have incorporated enable our loading monomer to be joined to a solid support<sup>17</sup> and form guanidinium linkages with additional synthetic nucleotides.<sup>18</sup>

In conclusion, we have confirmed the synthesis of N<sup>4</sup>-benzoyl-2'-O-(*tert*-butyldimethylsilyl)-5'-N-(4-monomethoxytritylamino)-3'-O-succinyl-5'-deoxycytidine by means of high resolution mass-spectroscopy and proton nuclear magnetic resonance.<sup>19</sup> Our method provides an efficient means of producing an RNG (and also a P3' → N5' phosphoramidate) monomer with high-yields and high purity.

## Acknowledgments

Funding was provided by the Chemistry Program at CSU Channel Islands. We thank Scott Duffer and the University of California Santa Barbara for assistance in obtaining spectral data.

## References and notes

- (a) Opalinska, J. B.; Gewirtz, A. M. *Nat. Rev. Drug Discov.* **2002**, *1*, 503; (b) Hokaiwado, N.; Takeshita, F.; Banas, A.; Ochiya, T. *IDrugs* **2008**, *11*, 274.
- (a) Goodchild, J. *Methods Mol. Biol.* **2011**, *764*, 1; (b) Fiset, P. O.; Soussi-Gounni, A. *Rev. Biol. Biotechnol.* **2001**, *1*, 27.
- Letai, A. G.; Palladino, M. A.; Fromm, E.; Rizzo, V.; Fresco, J. R. *Biochemistry* **1988**, *27*, 9108.
- (a) Inoue, H.; Hayase, Y.; Imura, A.; Iwai, S.; Miura, K.; Ohtsuka, E. *Nucleic Acids Res.* **1987**, *15*, 6131; (b) Prakash, T. P. *Chem. Biodivers.* **2011**, *8*, 1616.
- Duca, M.; Vekhoff, P.; Oussedik, K.; Halby, L.; Arimondo, P. B. *Nucleic Acids Res.* **2008**, *36*, 5123.
- (a) Linkletter, B. A.; Szabo, I. E.; Bruice, T. C. *Nucleic Acids Res.* **2001**, *29*, 2370; (b) Szabo, I. E.; Bruice, T. C. *Bioorg. Med. Chem.* **2004**, *12*, 1475; (c) Linkletter, B. A.; Szabo, I. E.; Bruice, T. C. *J. Am. Chem. Soc.* **1999**, *121*, 3888.
- Kojima, N.; Szabo, I. E.; Bruice, T. C. *Tetrahedron* **2002**, *58*, 867.
- Janowski, B. A.; Huffman, K. E.; Schwartz, J. C.; Ram, R.; Hardy, D.; Shames, D. S.; Minna, J. D.; Corey, D. R. *Nat. Chem. Biol.* **2005**, *1*, 216.
- Inoue, H.; Hayase, Y.; Imura, A.; Iwai, S.; Miura, K.; Ohtsuka, E. *Nucleic Acids Res.* **1987**, *15*, 6131.
- Barawkar, D. A.; Bruice, T. C. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 11047.
- Tomizu, M.; Negoro, Y.; Osaki, T.; Orita, A.; Ueyama, Y.; Nakagawa, O.; Imanishi, T. *Nucleosides Nucleotides Nucleic Acid* **2007**, *26*, 893.
- For the Mitsunobu reaction incorporating tetrachlorophthalimide: (a) Jia, Z. J.; Kelberlau, S.; Olsson, L.; Anilkumar, G.; Fraser-Reid, B. *Synlett* **1999**, 565; (b) Tetzlaff, C. N.; Schwöpe, I.; Blecinski, C. F.; Steinberg, J. A.; Richert, C. *Tetrahedron Lett.* **1998**, *39*, 4215.
- Diisopropyl azodicarboxylate was chosen to prevent the reaction from favoring the formation of a side product containing a hydrazylmethyl group. See: Swamy, K. C.; Kumar, N. N.; Balaraman, E.; Kumar, K. V. *Chem. Rev.* **2009**, *109*, 2551.
- The 47% yield is likely due to the formation of a side product in which the 3'-hydroxyl on the sugar receives the modification.
- Our products have remained stable in dry anoxic environments.
- Pon, R. T.; Yu, S. *Nucleic Acids Res.* **2004**, *32*, 623.
- The incorporation of 3'-succinyl linker enables a molecule to be tethered to controlled pore glass for the solid-phase synthesis of ribooligonucleotides. See: (a) Sharma, P.; Sharma, A. K.; Malhotra, V. P.; Gupta, K. C. *Nucleic Acids Res.* **1992**, *20*, 4100; (b) Reddy, P. M.; Bruice, T. C. *J. Am. Chem. Soc.* **2004**, *126*, 3736.
- Kearney, P. C.; Fernandez, M.; Flygare, J. A. *J. Org. Chem.* **1998**, *63*, 196.
- Spectral data for selected compounds: N<sup>4</sup>-Benzoyl-2'-O-isopropylidene-cytidine (**1**) HRMS (ESI) *m/z* Calcd for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O<sub>6</sub> (M+Na)<sup>+</sup> 410.1322. Found 410.1311. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): 11.29 s, 1H (NH); 8.30 d, 1H, *J* = 7.4 (H-6); 8.02 d, 2H, *J* = 6.8 (BzH); 7.62–7.50 m, 3H (BzH); 7.35 d, 1H, *J* = 7.2 (H-5); 5.85 d, 1H, *J* = 1.6 (H-1'); 5.12 t, 1H, *J* = 5.0 (OH-5'); 4.90 dd, 1H, *J* = 4.6, 1.6 (H-3'); 4.76 q, 1H, *J* = 3.0 (H-2'); 4.22 d, 1H, *J* = 3.2 (H-4'); 3.65–3.56 m, 2H (H-5'); 1.48 s, 3H (CH<sub>3</sub>); 1.28 s, 3H (CH<sub>3</sub>). N<sup>4</sup>-Benzoyl-5'-tetrachlorophthalimido-2'-O-isopropylidene-5'-deoxycytidine (**2**) HRMS (ESI) *m/z* Calcd for C<sub>27</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7</sub>Cl<sub>4</sub> (M+H)<sup>+</sup> 653.0164. Found 653.0189 (base peak of 4 Cl isotopes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 11.62 s, 1H (NH); 7.94 d, 1H, *J* = 7.0 (H-6); 7.67 d, 2H, *J* = 7.0 (BzH); 7.62–7.48 m, 4H (BzH and H-5); 5.54 d, 1H, *J* = 1.6 (H-1'); 5.27 dd, 1H, *J* = 7.2, 1.6 (H-3'); 5.05 q, 1H, *J* = 3.0 (H-2'); 4.48 m, 1H (H-4'); 4.30–4.00 m, 2H (H-5'); 1.54 s, 3H (CH<sub>3</sub>); 1.35 s, 3H (CH<sub>3</sub>). N<sup>4</sup>-Benzoyl-5'-tetrachlorophthalimido-5'-deoxycytidine (**3**) HRMS (ESI) *m/z* Calcd for C<sub>24</sub>H<sub>16</sub>N<sub>4</sub>O<sub>7</sub>Cl<sub>4</sub> (M+Na)<sup>+</sup> 634.9665. Found 634.9667 (base peak of 4 Cl isotopes). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>): 11.29 s, 1H (NH); 8.25 d, 1H, *J* = 7.8 (H-6); 8.02 d, 2H, *J* = 7.2 (BzH); 7.66–7.47 m, 3H (BzH); 7.41 d, 1H, *J* = 7.6 (H-5); 5.74 d, 1H, *J* = 3.0 (H-1'); 5.59 br s, 1H (OH-3'); 5.29 br s, 1H (OH-2'); 4.20–4.16 m, 2H (H-5'); 4.13–3.97 m, 3H (H-2', H-3', H-4'). N<sup>4</sup>-Benzoyl-2'-O-(*tert*-butyldimethylsilyl)-5'-tetrachlorophthalimido-5'-deoxycytidine (**4**) HRMS (ESI) *m/z* Calcd for C<sub>30</sub>H<sub>30</sub>N<sub>4</sub>O<sub>7</sub>SiCl<sub>4</sub> (M+Na)<sup>+</sup> 749.0530. Found 749.0522 (base peak of 4 Cl isotopes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 8.18 d, 1H, *J* = 7.6 (H-6); 8.91 d, 2H, *J* = 7.0 (BzH); 7.65–7.47 m, 4H (BzH and H-5); 5.64 d, 1H, *J* = 1.2 (H-1'); 4.42 dd, 1H, *J* = 1.2, 3.8 (H-2'); 4.32–4.16 m, 1H (H-3'); 4.12–4.07 m, 1H (H-4'); 4.03–3.88 m, 2H (H-5'); 0.92 s, 9H (Si(CH<sub>3</sub>)<sub>3</sub>); 0.25 s, 3H (SiCH<sub>3</sub>); 0.17 s, 3H (SiCH<sub>3</sub>). N<sup>4</sup>-Benzoyl-2'-O-(*tert*-butyldimethylsilyl)-5'-amino-5'-deoxycytidine (**5**) LRMS (ESI) *m/z* Calcd for C<sub>22</sub>H<sub>32</sub>N<sub>4</sub>O<sub>5</sub>Si (M+Na)<sup>+</sup> 461. Found 461. N<sup>4</sup>-Benzoyl-2'-O-(*tert*-butyldimethylsilyl)-5'-N-(4-monomethoxytritylamino)-5'-deoxycytidine (**6**) HRMS (ESI) *m/z* Calcd for C<sub>42</sub>H<sub>48</sub>N<sub>4</sub>O<sub>6</sub>Si (M+Na)<sup>+</sup> 755.3235. Found 755.3242. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 7.91 d, 1H, *J* = 7.6 (H-6); 7.75 d, 2H, *J* = 7.8 (BzH); 7.61–7.22 m, 16H (ArH, BzH and H-5); 6.87 d, 2H, *J* = 8.8 (ArH); 5.78 d, 1H, *J* = 1.2 (H-1'); 4.25 dd, 1H, *J* = 1.2, 3.6 (H-2'); 4.17–4.13 m, 1H (H-3'); 4.10–4.06 m, 1H (H-4'); 3.80 s, 3H (MMTr-OCH<sub>3</sub>); 3.73–3.53 m, 2H (H-5'); 0.94 s, 9H (Si(CH<sub>3</sub>)<sub>3</sub>); 0.30 s, 3H (SiCH<sub>3</sub>); 0.17 s, 3H (SiCH<sub>3</sub>). N<sup>4</sup>-Benzoyl-2'-O-(*tert*-butyldimethylsilyl)-5'-N-(4-mono-methoxytritylamino)-3'-O-succinyl-5'-deoxycytidine (**7**) HRMS (ESI) *m/z* Calcd for C<sub>46</sub>H<sub>52</sub>N<sub>4</sub>O<sub>9</sub>Si (M+Na)<sup>+</sup> 833.3576. Found 833.3585. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 8.69 d, 1H, *J* = 7.6 (H-6); 7.97 d, 2H, *J* = 8.4 (BzH); 7.58–7.20 m, 16H (ArH, BzH and H-5); 6.86 d, 2H, *J* = 8.8 (ArH); 5.78 d, 1H, *J* = 1.2 (H-1'); 4.88 dd, 1H, *J* = 4.8, 4.0 (H-3'); 4.43 dd, 1H, *J* = 4.4, 1.2 (H-2'); 4.40–4.36 m, 1H (H-4'); 3.78 s, 3H (MMTr-OCH<sub>3</sub>); 3.64–3.25 m, 2H (H-5'); 2.57 s, 4H (CO(CH<sub>2</sub>)<sub>2</sub>); 0.90 s, 9H (Si(CH<sub>3</sub>)<sub>3</sub>); 0.21 s, 3H (SiCH<sub>3</sub>); 0.07 s, 3H (SiCH<sub>3</sub>).